Bernstein raised the firm’s price target on DexCom (DXCM) to $86 from $84 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom: Reset Expectations, Strengthened Fundamentals, and Operating Leverage Support Reiterated Buy Rating
- DexCom call volume above normal and directionally bullish
- Dexcom Names Jacob Leach as Incoming Chief Executive
- Claims Jabil losing share at Dexcom ‘not happening,’ says Raymond James
- DexCom price target raised to $78 from $75 at Mizuho